S. Morgan

发表

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Manish R. Patel, J. Barrett, D. Hayes, 2018, Clinical Cancer Research.

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity

M. Millward, Lilin Zhang, H. Gan, 2019, Clinical Cancer Research.

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib

P. Hoff, S. Spencer, S. Morgan, 2014, British Journal of Cancer.

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

S. Im, G. Schiavon, H. Weir, 2018, Clinical Cancer Research.

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

P. Hoff, S. Morgan, J. Jürgensmeier, 2013, British Journal of Cancer.

Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).

P. Hoff, L. Pike, S. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.

D. Cunningham, N. Turner, S. Popat, 2013 .

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

David M. Wilson, P. Hoff, S. Dearden, 2013, European journal of cancer.

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

S. Barry, Paul D. Smith, J. Kendrew, 2016, Cell metabolism.

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

T. Powles, E. Jonasch, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation

C. West, R. Swindell, G. Betts, 2014, Virchows Archiv.

Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples

Emma Donald, L. Kam-Morgan, M. Eisenberg, 2012, Clinical medicine insights. Pathology.

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Jianxing He, 2020, Investigational New Drugs.

Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer

A. Jimeno, M. Hidalgo, M. Warren, 2009, Clinical Cancer Research.

Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study

C. Gwaltney, A. Barzi, J. Trojan, 2021, Quality of Life Research.

cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).

T. Choueiri, H. Burris, M. Millward, 2015 .

P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1

M. Kudo, R. Lencioni, B. Sangro, 2020 .

A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.

R. Lencioni, J. Knox, N. Kokudo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).

T. Powles, E. Jonasch, T. Choueiri, 2017 .

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy

P. Hoff, S. Morgan, A. Pommier, 2013, British Journal of Cancer.

Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

D. Cunningham, J. Bar, G. Goss, 2014, Clinical colorectal cancer.

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.

A. Zwinderman, P. Tak, D. Gerlag, 2004, Arthritis and rheumatism.

A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2.

R. Lencioni, J. Knox, N. Kokudo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)

T. Powles, E. Jonasch, T. Choueiri, 2014 .

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

H. Grabsch, S. Im, C. Womack, 2014, British Journal of Cancer.

OA 09.06 A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC

Yi-long Wu, Jian-hua Chang, Wei Li, 2017 .

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

David M. Wilson, P. Hoff, S. Dearden, 2013, European journal of cancer.

D. Cunningham, J. Bar, G. Goss, 2014, Clinical colorectal cancer.

Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts.

H. Grabsch, Y. Bang, S. Im, 2012 .

Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.

Yi-long Wu, Jin-Ji Yang, Amir Handzel, 2016 .